Drug General Information (ID: DDIZJO1SEU)
  Drug Name Chloral hydrate Drug Info Azilsartan medoxomil Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Anxiolytics/Sedatives/Hypnotics Antihypertensive Agents
  Structure

 Mechanism of Chloral hydrate-Azilsartan medoxomil Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Chloral hydrate Azilsartan medoxomil
      Mechanism 1 Antihypertensive agent Antihypertensive agent
Angiotensin II receptor  Antagonist
      Key Mechanism Factor 1
Factor Name Angiotensin II receptor Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Chloral hydrate and Azilsartan medoxomil 
      Mechanism 2 Hypotensive effects Antihypertensive agent
Angiotensin II receptor  Antagonist
      Key Mechanism Factor 2
Factor Name Angiotensin II receptor Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Chloral hydrate and Azilsartan medoxomil 

Recommended Action
      Management Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

References
1 Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6. [PMID: 2211552]
2 Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139. [PMID: 2005082]
3 Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1. [PMID: 1770159]